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Background: Participation rates in colorectal cancer screening (CRC) are low. Relatively little is known about
screening uptake across varying levels of risk and across population groups. The purpose of the current study was
to identify factors associated with (i) ever receiving colorectal cancer (CRC) testing; (ii) risk-appropriate CRC
screening in accordance with guidelines; and (iii) recent colonoscopy screening.
Methods: 1592 at-risk persons (aged 56–88 years) were randomly selected from the Hunter Community Study
(HCS), Australia. Participants self-reported family history of CRC was used to quantify risk in accordance with
national screening guidelines.
Results: 1117 participants returned a questionnaire; 760 respondents were eligible for screening and analysis. Ever
receiving CRC testing was significantly more likely for persons: aged 65–74 years; who had discussed with a doctor
their family history of CRC or had ever received screening advice. For respondents “at or slightly above average
risk”, guideline-appropriate screening was significantly more likely for persons: aged 65–74 years; with higher
household income; and who had ever received screening advice. For respondents at “moderately or potentially
high risk”, guideline-appropriate screening was significantly more likely for persons: with private health insurance
and who had discussed their family history of CRC with a doctor. Colonoscopy screening was significantly more
likely for persons: who had ever smoked; discussed their family history of CRC with a doctor; or had ever received
screening advice.
Conclusions: The level of risk-appropriate screening varied across populations groups. Interventions that target
population groups less likely to engage in CRC screening are pivotal for decreasing screening inequalities.Background
Worldwide, colorectal cancer (CRC) is a significant health
burden with over one million persons diagnosed annually
[1]. The five-year survival rate for localised disease is high,
yet few CRCs (less than 40%) are detected at this stage [2].
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reproduction in any medium, provided the orof precancerous polyps [3,4] and increase early detection of
disease [5,6]. Australian National Health and Medical
Research Council (NHMRC) screening guidelines [7]
recommend that asymptomatic persons “at or slightly
above average risk” receive either FOBT screening
biennially or sigmoidoscopy (preferably flexible) every
five years commencing at age 50 years [7]. For persons
at “moderately increased risk”, colonoscopy is endorsed
every five years starting at age 50 or at an age ten years
younger than the age of first diagnosis of bowel cancer in
the family, whichever comes first [7]. Endoscopy screening
for persons at “potentially high risk” is recommended atal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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guidelines. However, age at screening commencement,
test type and repeat testing interval are dependent on the
type of family-specific mutation identified [7].
Australia’s National Bowel Cancer Screening Program
In Australia, Medicare administers the National Bowel
Cancer Screening Program (NBCSP) Register [8]. Medicare
selects eligible participants from either the Medicare
enrolment records or the Department of Veterans’ Affairs
[8]. The NBCSP Register is responsible for mailing of
screening invitations and FOBT kits, the recording of
participants’ details and the issuing of reminder letters [8].
As part of the NBCSP, participants are encouraged to
nominate their usual primary care provider on their
participants details form; however, this is not compulsory
[8]. The recently re-funded NBCSP offers persons turning
50, 55 and 65 years of age via mail a one-off immunochem-
ical Faecal Occult Blood Test (FOBT) screening invitation
[9]. It is important to note that the limited format of the
NBCSP (restriction of screening to persons in selected age
brackets across the at-risk population), [9] is not consistent
with the NHMRC recommendation of biennial FOBT
screening of all Australians in the at-risk population [7]. A
recent study examining the costs and outcomes from full
(rather than limited) implementation of a biennial FOBT
screening for adults in the at-risk population (50–74 years)
identified a likely mortality reduction of 25% and saving of
500 deaths per year [10].
Screening participation in Australia
Participation rates in Australia’s NBCSP appear to have
reached a plateau since the pilot program’s introduction
[9,11-13]. The pilot program received a response rate of
45%, with the roll-out of the NBCSP (with screening
offered to persons 50 and 65 years of age) in 2006 receiving
a slightly lower rate of 41% [12]. The rate of participation
only marginally increased in 2008 to 42.9% when the
program widened to offer screening to persons aged 55
years of age [11]. Most recent estimates suggest a similar
rate of low participation (40.1%) [9]. The experience in
other countries with national screening programs offering
repeated FOBT screening to a wider section of the at-risk
population suggests that much higher screening rates are
achievable. For example, FOBT screening rates in the
United Kingdom and Finnish screening programs are
currently 52% and 71% respectively [14,15]. In Australia,
previous community- based evaluations have also indicated
low rates of CRC screening, with 5 to 20% of individuals
ever undertaking FOBT [16-18]. The most recent
assessment in New South Wales (NSW) indicated that
18% of persons aged over 50 years had undertaken
FOBT in the previous five years [19]. In relation to
colonoscopy screening in Australia, two population-basedassessments in NSW have suggested under screening
among persons at elevated levels of risk [16,19].
Given low rates of CRC screening, it is important to
identify factors which may influence screening uptake.
Previous studies have indicated that the following factors
influence CRC screening behaviour: socio-demographic
characteristics (e.g. older age, higher education, higher
income); lifestyle factors (e.g. smoking history, chronic
disease); family history (e.g. personal or family history of
CRC); awareness (e.g. knowledge of CRC and perceived
risk of developing CRC) and health care utilisation
(e.g. usual source of care, number of GP visits, and health
care coverage) [20-26]. In the Australian context, a small
number of studies have explored determinants of CRC
screening uptake [17-19,27,28] with little known about
predictors of screening behaviour for persons at varying
levels of risk [16]. Since the introduction of the NBCSP in
2006, no community- or population-based assessments in
Australia have been conducted. Recent evidence pertaining
to FOBT screening uptake and inequalities in participation
have been confined to annual NBCSP monitoring reports,
which report screening rates among a limited section of
the at-risk population (persons 50, 55 and 65 years of age)
[9,11-13]. Further, since the NHMRC guidelines’ im-
plementation in 1999, only one study has assessed the
predictors of risk-appropriate screening for persons at each
level of risk in accordance with guideline-recommendation
[16]. The identification of factors associated with
risk-appropriate screening is of critical importance
for future planning and implementation of tailored
CRC screening programs.
This study aimed to assess among a large community-
based cohort of at-risk persons (aged 56–88 years), the
factors associated with: (1) ever receiving any CRC testing;
(2) receiving screening in accordance with screening
guidelines; and (3) recent use of colonoscopy screening.
Methods
The University of Newcastle and Hunter New England
Population Health Human Research Ethics Committees
granted ethical approval.
Study population
The Hunter Community Study (HCS) is a longitudinal
community cohort aged 55–85 years at baseline in the
Hunter Region, New South Wales (NSW), Australia. The
sampled population, Hunter Community Study participants
are at-risk of developing CRC with clinical practice guide-
lines recommending all persons commence CRC screening
from the age of 50 years [7]. HCS participants were
randomly selected from the NSW State electoral roll
between December 2004 and December 2007. A modified
Dillman recruiting strategy [29] was used for this study,
whereby two letters of introduction and an invitation to
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speaking English and living in a residential aged-care facility
were deemed ineligible. Following consent to participate,
individuals were asked to complete two self-reported
questionnaires and were asked to return these when they
attended the HCS data collection centre, at which time a
series of clinical measures were obtained. For further details
on the HCS cohort and an exhaustive list of measures
obtained from HCS participants, see the cohort profile [30].
The HCS cohort profile reflects state and national profiles
for gender and marital status but is slightly younger in age
[30]. For the current study, a randomly selected sub-sample
of the HCS (n = 1592) aged 56–88 years (reflective of age
since HCS data collection point) were mailed a question-
naire during November, 2009. The sample size of 1592 was
chosen to investigate delay in seeking medical advice for
primary symptoms of CRC in additional studies using the
HCS cohort [31,32] in order to achieve a power of 80%, so
that the proportion of individuals who delay seeking
medical advice for symptoms or treatment for CRC will
be estimated with 95% confidence intervals.
Questionnaire
Questions and responses options are presented in the
study questionnaire (see Additional file 1). Respondents
were asked whether they had ever undertaken FOBT,
colonoscopy or sigmoidoscopy. Those ever undertaking
each test were asked to specify timing of most recent
testing and “Did you have your last X test because you
had a symptom” (Yes/ No). All respondents were asked
about their family history of CRC (see Additional file 1)
to allocate each respondent to a level of risk (see Table 1)
in accordance with screening guidelines [7].
Predictors of CRC screening behaviour
Based on existing literature, the following items selected
from the HCS databank, assessed at HCS baseline wereTable 1 Respondents risk allocation in accordance with CRC s
Risk category*
At or slightly above average risk • No personal history o
• Either no close relativ
relative with bowel can
Moderately increased risk • One first-degree relati
(without potentially hig
• Two first-degree relati
the same side of the fa
Potentially high risk • Three or more first-de
relatives on the same s
• Two or more first-deg
with bowel cancer, incl
or at least one-relative
pelvis, ureter, biliary tra
* Risk features potentially placing persons at possible increased risk including: perso
adenomatous polyposis (FAP) were not assessed in the survey. ** HNPCC (Hereditarinvestigated: Socio-demographic characteristics: age, gender,
education, marital status, country of birth, household
income, retirement, private health insurance status,
tobacco or alcohol use; Clinical characteristics: number of
general practice visits over the past 12 months, previous
cancer diagnosis (excluding CRC), body mass index, and
presence of a chronic health-condition; and Psychosocial
characteristics: physical health (SF-36) and mental health
(K-10 Kessler Scale). Predictors ascertained at survey
completion included: risk category, discussion of family
history of CRC with doctor and notification of any
“increased risk” (Never discussed/ discussed and informed
of possible “increased risk”/ discussed and not informed of
any possible “increased risk”), and ever received screening
advice from doctor (Yes/No).
Statistical analysis
Descriptive statistics including frequencies, percentages,
means, and standard deviations were used to describe
the characteristics of participants. Chi-squared testing
was used to assess any responder bias in relation to age,
gender, and level of education. “Ever received CRC testing”
was calculated by combining the proportion of respondents
indicating “Yes” to undertaking any of the following CRC
tests (i.e. FOBT, sigmoidoscopy or colonoscopy) divided by
the total number of respondents. Respondents who had not
provided any information on any of these CRC tests were
excluded from analysis. The proportion of respondents
screened in accordance with screening guidelines
(Yes/ No) was assessed by risk category [7] as follows:
“at or slightly above average risk” (FOBT within two
years or sigmoidoscopy preferably flexible within five years)
and “moderately increased risk/ potentially high risk”
(colonoscopy within 5 years). Self reported family
history of CRC was used to allocate respondents to a
risk category in accordance with screening guidelines.
Respondents with missing values relating to type orcreening guidelines
f bowel cancer.
es with bowel cancer or one first-degree or second-degree
cer diagnosed at age 55 years or older.
ve diagnosed before the age of 55 years
h-risk features listed below), or
ves or one first- and one second-degree relative(s) on
mily (without potentially high-risk features listed below).
gree or a combination of first-degree and second-degree
ide of the family diagnosed with bowel cancer (suspected HNPCC**), or
ree or second-degree relatives on the same side of the family diagnosed
uding the following risk feature: bowel cancer before the age of 50 years
with cancer of the endometrium, ovary, stomach, small bowel, renal
ct or brain.
nal history of adenoma, inflammatory bowel disease or suspected familial
y non-polyposis colorectal cancer) also known as Lynch syndrome.
Courtney et al. BMC Public Health 2013, 13:248 Page 4 of 10
http://www.biomedcentral.com/1471-2458/13/248number of relative(s) diagnosed or age at their diagnosis
were excluded from analysis. Multiple logistic regression
modelling was used to assess the association between
socio-demographic, clinical and psychosocial characteristics
and each study outcome: ever received CRC test,
screened in accordance with guidelines for level of risk
(“at or slightly above average risk” and “moderately/
potentially increased risk”), and recent colonoscopy
screening (within previous five years). Variables with a
p value <.25 following simple logistic regression analysis
(see Additional file 2) were entered into a stepwise
multiple logistic regression analysis. Forward and
Backward stepwise regression was used on complete
cases so that the likelihood ratio test could be used
to determine the best fit from one iteration to the next.
Both the forward selection and backward elimination re-
gression analysis produced equivalent results. Results from
the backward stepwise elimination model were reported.
Variables that met the significance cut point (p value < .05)
were included in the final model. Data were analysed using
STATA 11 (STATA, Texas, USA).
Results
Characteristics of the sample
Of the 1592 mailed surveys, 1117 respondents completed
and returned a survey (response rate = 70%). Respondents
previously diagnosed with CRC (n = 24) or reporting they
had undergone major abdominal surgery (n = 8) were
excluded from analysis, leaving a total sample of 1085
participants with data. Responder bias was assessed on the
following key characteristics: gender, age (56–64, 65–74,
75–88), and education (secondary schooling completed,
secondary schooling not competed, trade qualification or
TAFE, university or other tertiary education and other).
Pearson’s χ2 test found no significant differences relating to
gender (χ2 = .09; df =1 ; p = .76 ) or education (χ2 = 8.75;
df = 4; p = .07). However, for age, respondents were
significantly more likely to be of a younger age compared
to non-respondents (χ2 = 11.12; df = 2; p < .01).
Inclusion and exclusion for CRC screening
Respondents were classified as asymptomatic and eligible
for screening if they had not reported the following:
undertaking FOBT, sigmoidoscopy or colonoscopy due
to a symptom episode in the previous five years; any
bowel related condition; previous history of CRC; or
consulting a doctor for their first primary symptom episode
of CRC (rectal bleeding or change in bowel habit) in the
previous five years. Following exclusion of such persons, a
total sample of 777 asymptomatic persons were identified.
17 asymptomatic persons were excluded from analysis due
to insufficient family history information available to derive
a level of risk in accordance with CRC screening guidelines.
Table 2 describes the characteristics of respondentsallocated to a level of risk in accordance with screening
guidelines (n = 760) and eligible for analysis.
Ever received CRC testing
Overall, 63% (475/ 760) of respondents allocated to
a level of risk had ever received any CRC testing
(FOBT/ sigmoidoscopy or colonoscopy). The proportion
ever undertaking CRC testing by risk category were: “at or
slightly above average risk” 61% (431/ 707), “moderately
increased risk” 82% (28/34) and “potentially high risk” 84%
(16/19). Simple logistic regression analyses identified items
with a p value < .25 which were entered into multiple
logistic regression modelling. Table 3 presents the results of
this analysis. Persons significantly more likely to have ever
been tested for CRC were aged between 65–74 years of age
and had ever received screening advice from a doctor.
Persons who had discussed their family history of CRC
with a doctor, irrespective of whether they were informed
of any possible “increased risk”, were significantly more
likely to be tested than those never having discussed their
family history with a doctor.
CRC screening in accordance with national screening
guidelines
Of the 707 respondents “at or slightly above average
risk”, 697 provided information on either FOBT or
sigmoidoscopy screening, with 21% (145/697) of respon-
dents screened in accordance with national screening
recommendation (see Table 4). Screening in accordance
with guideline recommendation was significantly more
likely to occur for “at or slightly above average risk”
persons: aged 65–74 years of age; with a higher household
income (> $70, 000 compared to <= $39, 999); and who
had ever received screening advice from a doctor.
Of the 53 respondents at “moderately increased risk/
potentially high risk” and providing colonoscopy screening
information, 45% (24/53) were screened in accordance with
screening recommendation. Screening in accordance with
guideline recommendation (colonoscopy within 5 years)
was significantly more likely to occur for persons who had
private health insurance and who had discussed their family
history of CRC with a doctor (see Table 5).
Recent colonoscopy screening irrespective of level of risk
Of the 760 respondents allocated to a level of risk,
752 respondents provided colonoscopy screening
information, with 16% (124/752) of respondents receiving
a colonoscopy within the previous five years. Table 6
presents the multiple logistic regression model for
recent colonoscopy screening (within 5 years) irrespective
of level of risk. Recent colonoscopy screening was
significantly more likely for persons: that had ever
smoked; discussed their family history of CRC with a
doctor regardless of whether informed of “increased
Table 2 Socio-demographic, clinical and psychosocial characteristics of the asymptomatic study population (n = 760)
Characteristic n %**
Socio-demographic
Gender* Male 363 48
Female 397 52
Age (years)* 56-64 317 42
65-74 268 36
75-88 168 22
Marital status* In Relationship 575 79
Not in Relationship 155 21
Education* Secondary schooling (not-completed) 164 22
Secondary schooling (completed) 162 22
Trade qualification or TAFE: 189 26
University or other tertiary study 181 25
Other or not applicable 33 5
Household income before tax ($)* <= 39, 999 389 57
40, 000 – 69, 999 152 22
>= 70,000 146 21
Country of birth* Australian 619 89
Other 76 11
Retired* Yes 453 62
Private health insurance* No-coverage 191 26
Coverage 531 74
Alcohol* Drink days per month Mean =11 SD =11
Smoking* Ever 346 48
Never 382 52
Clinical
Number of GP visits over the past 12 months* None to twice 187 25
Three to six 411 56
> six 137 19
Previous cancer (excluding CRC)* Yes 163 22
Risk Category At or slightly above average risk 707 93
Moderately increased risk 34 4
Potentially high risk 19 3
Discussion of family history of CRC with doctor Never discussed 523 70
Discussed, informed of ‘increased risk’ 133 18
Discussed, not informed of ‘increased risk’ 90 12
Ever received screening advice from doctor Yes 195 28
BMI* < 18.5 7 1
18.5 – 25 130 19
> 25 555 80
Chronic health condition* Yes 554 76
Psychosocial
SF-36 (physical health score)* Mean = 52 SD = 9
K-10 (mental health score)* Low or no risk (10–15) 555 75
Medium to high risk (16 +) 184 25
* Participant data collected at HCS baseline. ** Percentage of responses (excluding any missing values).
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Table 3 Multiple logistic regression model (n = 689)* of
factors associated with ever receiving CRC testing
Characteristic n** (%) OR (95% CI) p value
Age (years)
56-64 172 (57) 1
65-74 171 (71) 2.00 (1.36, 2.97) <.001
75-88 86 (59) 1.27 (.82, 1.96) .286
Discussion of family history
of CRC with doctor
Never discussed 248 (52) 1
Discussed/ informed of
possible ‘increased risk’
114 (90) 4.13 (2.12, 8.05) <.001
Discussed/ not informed of
possible increased ‘risk’
67 (83) 3.78 (2.02, 7.05) <.001
Ever received screening
advice from doctor
No 264 (53) 1
Yes 165 (88) 3.59 (2.11, 6.08) <.001
* Respondents excluded from model due to missing values (n = 71).
** Number of respondents ever received CRC testing.
Table 5 Multiple logistic regression model (n = 50*) of
factors associated with screening in accordance with
guidelines for persons at “moderately increased risk/
potentially high risk”
Characteristic n** (%) OR (95% CI) p value
Private health insurance
No-coverage 3 (18) 1
Coverage 19 (58) 8.46 (1.58, 45.39) .013
Discussion of family history
of CRC with doctor
Never discussed 3 (14) 1
Discussed/ informed
of ‘increased risk’
17 (68) 16.34 (3.19, 83.55) .001
Discussed/ not informed
of increased ‘risk’
2 (67) 17.50 (.83, 368.04) .066
* Respondents excluded from model due to missing values (n = 3).
** Number of respondents screened in accordance with guidelines.
Table 6 Multiple logistic regression model (n = 659)* for
colonoscopy screening (within 5 years) irrespective of
level of risk
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a doctor.
Discussion
The behaviour of health care providers including
discussing family history of CRC and making a CRC
screening recommendation were predictors of CRC
screening uptake, screening in accordance with guideline
recommendation and recent colonoscopy screening.
Individual and lifestyle characteristics associated with
some but not all of the above CRC screening outcomes
included: higher household income, age, private health
insurance and smoking.Table 4 Multiple logistic regression model (n = 586*) of
factors associated with screening in accordance with
guidelines for persons “at or slightly above average risk”
Characteristic n** (%) OR (95% CI) p value
Age (years)
56-64 46 (17) 1
65-74 59 (29) 2.71 (1.64, 4.49) <.001
75-88 21 (18) 1.57 (.83, 2.96) .166
Annual household income
before tax ($)
<= 39, 999 60 (18) 1
40, 000 – 69, 999 27 (21) 1.28 (.74, 2.21) .380
>= 70,000 39 (30) 2.59 (1.50, 4.49) <.001
Ever received screening
advice from doctor
No 72 (16) 1
Yes 54 (38) 3.00 (1.95, 4.64) <.001
* Respondents excluded from model due to missing values (n = 111).
** Number of respondents screened in accordance with guidelines.Factors associated with CRC screening behaviour
Health care provider recommendation for CRC screening
The variable most strongly associated with CRC testing
and screening was receiving screening advice from a health
care provider. This finding is consistent with previous
literature which identified physician encouragement as an
important predictor of CRC screening [20,22,24]. Strategies
such as general practitioner screening invitations sent to
patients [33,34] and provider reminder/ prompt systems
are effective in increasing the likelihood of screening
participation [35]. Relatively little is known about how
well CRC screening is included within practice-basedCharacteristic n** (%) OR (95% CI) p value
Smoking
Never 47 (14) 1
Ever 63 (20) 1.89 (1.15, 3.10) .012
Discussion of family history
of CRC with doctor
Never discussed 30 (6) 1
Discussed/ informed
of ‘increased risk’
65 (53) 7.20 (3.95, 13.09) <.001
Discussed/ not informed
of increased ‘risk’
15 (20) 2.30 (1.11, 4.76) .002
Ever received screening
advice from doctor
No 31 (6) 1
Yes 79 (44) 4.60 (2.65, 8.00) <.001
Private health insurance
No-coverage 17 (10) 1
Coverage 93 (19) 1.84 (.97, 3.50) .062
* Respondents excluded from model due to missing values (n = 93).
** Number of respondents receiving recent colonoscopy screening.
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delivery of CRC screening advice and implementation
of effective primary-care based interventions are likely
to be beneficial.
Discussion of family history of CRC with doctor
Persons who had discussed their family history of CRC
regardless of whether they were informed of possible
“increased risk” were more likely to be ever tested,
screened in accordance with guideline recommendation
(“moderately/ potentially high risk” persons) and screened
recently using colonoscopy. Such findings highlight the
importance of family history of CRC assessment in the
primary care setting. Studies of cancer risk assessment
tools suggest that such an approach is feasible and effective
for collection of family history of cancer information, auto-
mation of familial risk stratification and risk-appropriate
screening advice [38,39].
Age
Among persons who were “at or slightly above average
risk”, those who were older were more likely to ever be
tested and screened in accordance with CRC screening
guidelines, as per previous studies [19,24,40,41]. The
literature suggests that an inverted U-relationship is
observed, with the lowest rates of CRC screening participa-
tion found among persons 50–55 years and 70–80 years of
age [24,42]. Further, it has also been demonstrated that
non-adherence to repeat FOBT screening is evident for
persons aged less than 65 years [43]. Given the rapid
increase in CRC risk after age 50, the targeting of those
aged 50–65 years is of particular importance if optimal
screening rates are to be achieved.
Household income
A gradient in CRC screening participation has been
identified worldwide related to socio-economic status
[20,24,42]. Patient screening preference is sensitive to
out of pocket expenses [44] with lower participation
among disadvantaged persons [21,24]. In the current
study, persons “at or slightly above average risk” with
household incomes above >$70,000 were more likely to be
screened in accordance with guideline recommendation,
suggesting a need for interventions facilitating CRC
screening among low income households. In Australia,
annual NBCSP monitoring reports and cross-sectional
analysis of participation in this program have also
indicated significantly lower levels of CRC screening
participation among persons from the most deprived
socio-economic quintiles in the population [9,11-13,45]. It
is important to consider that this disparity in participation
among differing socio-economic groups in Australia and
the United Kingdom (UK) occurs in the presence of
universal programs offering FOBT screening at no cost[45]. A similar socio-economic gradient in screening
participation has also been identified for cervical and
breast cancer screening programs [21]. These findings,
lend support to the suggestion that direct economic
barriers alone do not explain the socio-economic
differential in participation [42]. Previous studies have
indicated that the provision of universal healthcare or
re-imbursement for the cost of screening has little
appreciable effect on eliminating equality in screening
participation [46-49]. It appears that some health service
access hurdles appear to dominate among disadvantaged
persons [42,50]. Additionally, it is argued that there are
distinct differences in healthcare-seeking behaviour and
beliefs among persons from lower socio-economic groups,
compared with those from higher socio-economic groups
[42,50]. Taken together, this suggests that strategies to
improve equality in screening must recognise factors other
than financial coverage [42]. It is paramount that future
formative research examines the beliefs and barriers to
CRC screening participation among lower socio-economic
persons, to assist in the development of effective interven-
tions [51,52]. When considering future decisions about
Australia’s NBCSP, it is critical that policy makers consider
the reasons for non-screening compliance among persons
from lower socio-economic status if increased equality in
participation is to eventuate.
Private health insurance
Persons with private health insurance were marginally
more likely to have recent colonoscopy screening. Previous
literature indicates that private health insurance is a strong
predictor of CRC screening [19,24,53]. Importantly, the
current finding that private health insurance is a predictor
for all colonoscopies but not for colonoscopies in accord-
ance with guidelines casts some doubt on the process by
which colonoscopies are decided. There is a pressing
need to identify ways to improve guideline-appropriate
use of colonoscopies.
Smoking
Previous studies have indicated that smokers tend to be less
compliant with CRC screening [19,24]. The increased likeli-
hood of recent colonoscopy screening among persons who
had ever smoked in the current study may be due to health
providers’ identification of this risk factor and provision of
colonoscopy screening. Alternatively, ex-smokers who have
already made a health behaviour change in their lives
may have an increased motivation for health screening
compared to persons who had never smoked.
Limitations
It should be acknowledged that responder bias place
some limitations on the interpretation of findings and
their generalisability. For the most part, the HCS is a
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comparison to Census data on a number of demographic
characteristics, with the exception of age [30]. Analysis
of responders’ bias identified that responders were more
likely to be younger than non-responders from the HCS
cohort. In addition, persons living in residential care
facilities and those from non-English speaking background
were excluded in this study. Previous literature has indi-
cated that non-English speaking persons are significantly
less likely to undertake CRC screening [11-13,19]. Future
population based CRC screening programmes could
benefit from strategies to improve CRC screening in
non-English speaking persons and migrant groups [19]. For
respondents undertaking FOBT, type of test undertaken
(guaiac or immunochemical) and the outcome of testing
(negative/ positive) was not assessed, and this should be
considered when interpreting the rate of colonoscopy
screening (previous five years), as it may be an independent
predictor for seeking a colonoscopy.
While it must be acknowledged that self-reported
screening behaviour may have some recall bias, it has
been shown to have reasonable agreement with physician
report and relatively high levels of sensitivity and specificity
[54,55]. Although two new studies and a recent meta-
analysis have indicated high levels of sensitivity and
specificity for self-reported screening behaviour,
[56-58] it is important to recognise that accuracy of
self-reported screening varies across patient characteristics
and test modalities [20]. A meta-analysis of validation
studies on self-reported CRC cancer screening use in the
United States found that self-report versus documented
history of screening had a high level of specificity
(endoscopy .90 and FOBT .78) and sensitivity (endoscopy
.82 and FOBT .79) [56].
To enhance recall, the current study adopted descriptions
of CRC tests to increase the accurate recall of CRC testing.
Self-reported family history of CRC was used to assign level
of risk. Previous studies have indicated self-reported family
history of CRC has relatively high levels of sensitivity and
specificity for reporting of affected first-degree relatives
[59-61]. However, the level of accuracy is substantially
reduced for affected second-degree relatives [59-61]. The
accuracy of reporting of age at diagnosis in CRC- affected
relatives has not been identified in the literature. Further,
the extent to which misleading family history information
reorients risk classification for relatives following verifica-
tion is largely unknown [61]. Therefore, it is possible that
the classification of risk may be inaccurate for a small
proportion of study respondents given the limitation of no
objective verification of self reported family history. For
respondents at “moderately increased/ potentially high
risk”, level of risk may have been overestimated for a small
minority of respondents. For respondents indicating that
both a first-degree relative and second-degree relativewere diagnosed with CRC, an assumption was made that
both relatives were diagnosed on the same side of the
family. This assumption may have over-estimated the level
of risk for some respondents.
Finally, the current study is subject to limitations associ-
ated with stepwise regression analysis including: parameter
estimation, error rate estimation and reliance on a single
best model [62-65]. Conducting stepwise regression models
with a large number of independent variables and a small
sample size, may over-estimate model fit [63,64]. However,
this limitation is difficult to overcome when applying statis-
tical modelling techniques to identify predictors associated
with rare occurrences in the population i.e. persons at
increased familial risk of disease. It is conceivable that
future large scale population-based studies examining CRC
screening behaviour across varying levels of familial risk will
assist in further defining the predictors of risk-appropriate
CRC screening.
Conclusions
Empirical randomised controlled trial evidence suggests
that the offering of repeated (annual or biennial) FOBT
screening to the at-risk population is effective in reducing
mortality and incidence associated with CRC [3,6,66,67].
In Australia, there is a pressing need for expansion of the
NBCSP and offering of repeated screening to the at-risk
population, if the CRC-related disease burden and
economic cost is to be reduced [68]. Multiple strategies
and messages targeting specific demographic groups as well
as healthcare provider factors are needed if increases in
overall screening participation are to be achieved. A press-
ing issue is the reduction of inequalities in CRC screening
participation to reduce inequality in health outcomes. High
quality research is required to unravel the barriers to CRC
screening, as well as the mechanisms by which screening
inequalities are maintained.
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